Entering text into the input field will update the search result below

Esperion Therapeutics, Inc. (ESPR) CEO Timothy Mayleben on Q1 2021 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET

Company Participants

Benjamin Church - Head, Corporate Communications & IR

Timothy Mayleben - President and Chief Executive Officer

Sheldon Koenig - Chief Operating Officer

Richard Bartram - Chief Financial Officer

Conference Call Participants

Michael Yee - Jefferies

Jason Butler - JMP Securities

Geoff Meacham - Bank of America

Joe Thome - Cowen and Company

Derek Archila - Stifel

Jeff Hung - Morgan Stanley


Ladies and gentlemen, thank you for standing by, and welcome. At this time, all participants are in a listen-only mode. Following the presentation, there will be a question-and-answer session. Please be advised that today's conference call may be recorded.

I would now like to hand the conference call over to Ben Church, Investor Relations and Corporate Communications at Esperion. Please go ahead, sir.

Benjamin Church

Thank you, operator. Good afternoon, and welcome to Esperion's First Quarter 2021 Financial Results and Company Update Conference Call. I am Ben Church, and I am responsible for Investor Relations and Corporate Communications here at Esperion.

With me on today's call are Tim Mayleben, President and Chief Executive Officer; Sheldon Koenig, Chief Operating Officer; and Rick Bartram, Chief Financial Officer. I want to remind callers that the information discussed on the call today is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by their cautionary statements contained in today's press release and SEC filings. The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 4, 2021.

Recommended For You

Comments (5)

Summary of call. "Technical difficulty"
Sandy Singh Siwach profile picture
Lots of positive sounding stats, but no color on revenues going forward. No guidance on total addressable market. These guys always sound positive but so far have completely failed to deliver. I wonder for how long they will keep blaming COVID for the lack of performance?
@Sandy Singh Siwach FYI, they are done blaming covid. It is now Easter! ..."We were actually exhibiting approximately a 3% week-over-week growth and our hypothesis there was that it was flat due to Easter and many vacations et cetera that were taking place."
PovLis profile picture
@fcbergeron did they mentioned a billion dollars potential market out there? How these analysts came up with the target price where one put it at $20 and another one put it at $110? And many others put PT in between.
@Sandy Singh Siwach But COVID is the problem! If ESPR were an airline, a cruise line, or a hotel chain, would you accuse management of being incompetent because revenue plummeted during the pandemic? Of course not. Selling a new drug under current conditions is daunting. Sales reps can’t visit docs, patients are putting off consultations, and medical conferences have been canceled. As we emerge from the pandemic, ESPR’s sales should improve dramatically — and if they don’t, well, maybe it’ll be time to change management. Until then, let’s keep things in perspective.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.